Prospective multicentre study combines EV protein biomarkers and machine learning for preclinical oesophageal cancer detection
The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors. The model was evaluated in prospective multicentre diagnostic cohorts and two population cohorts; the longitudinal cohort contained baseline samples from 30 people who later developed oesophageal squamous cell carcinoma, with a reported median lead time of 34.9 months and AUC 0.864. The paper also reports external diagnostic validation in two cohorts.
Technology: Multi-criteria decision-making Classification Fusion (MCF) machine-learning framework; 289 candidate feature-selector/classifier pairs were compared and three base models fused
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors.
- Still unknown: This is a prospective observational diagnostic study, not an intervention trial or proof that screening improves outcomes. The longitudinal preclinical cohort had 30 incident cases and matched controls; performance estimates require external replication in larger populations. The source reports an association and lead time, not guaranteed individual prediction. Primary publisher full text and abstract checked; no independent replication assessed.
- AI role: The MCF framework integrated newly identified EV biomarkers with clinical variables, selected and fused machine-learning classifiers, and produced the risk score evaluated in diagnostic and prospective population cohorts. BarFlare is the high-sensitivity EV assay platform, not the AI model.
Evidence sources: https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.70246
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.